Longboard pharmaceuticals provides corporate update and reports second quarter 2023 financial results

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financial results for the second quarter ended june 30, 2023. “we have made great progress in the first half of 2023 and look forward to completing enrollment for the pacific study in the coming weeks resulting in topline data around the end of.
LBPH Ratings Summary
LBPH Quant Ranking